Cidara Therapeutics, Inc.
CDTX
$66.27
$2.143.34%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 0.88% | -47.52% | |||
| Gross Profit | -0.88% | 47.52% | |||
| SG&A Expenses | 5.23% | -15.45% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 23.94% | -53.36% | |||
| Operating Income | -23.94% | 53.36% | |||
| Income Before Tax | -9.53% | 55.16% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -9.53% | 55.16% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -9.53% | 55.11% | |||
| EBIT | -23.94% | 53.36% | |||
| EBITDA | -24.01% | 53.39% | |||
| EPS Basic | 0.11% | 69.20% | |||
| Normalized Basic EPS | -15.16% | 69.24% | |||
| EPS Diluted | 0.11% | 69.20% | |||
| Normalized Diluted EPS | -15.16% | 69.24% | |||
| Average Basic Shares Outstanding | 9.66% | 45.74% | |||
| Average Diluted Shares Outstanding | 9.66% | 45.74% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||